← Back to Clinical Trials
Recruiting NCT05964712

NCT05964712 Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05964712
Status Recruiting
Phase
Sponsor Istituto Auxologico Italiano
Condition Acromegaly
Study Type OBSERVATIONAL
Enrollment 30 participants
Start Date 2019-06-18
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 90 Years
Study Type OBSERVATIONAL
Interventions
Medical surgery therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 30 participants in total. It began in 2019-06-18 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Acromegaly is a rare chronic disease due to excessive secretion of growth hormone (GH) and insulin-like growth factor-I (IGF-I), caused in over 98% of cases by GH-secreting pituitary adenoma. Prolonged exposure to GH/IGF-I excess is the cause of increased mortality and morbidity in these patients. Arthropathy occurs in about 75% of acromegalic patients. Any joint may be affected, with the development of osteoarthritis, arthralgia, and an increase in fracture risk. The aims of the present project are to evaluate the dimensions of hands and feet with the 3D scanner method and to perform a quantitative analysis of movement through Gait Analysis technique in de novo patients with acromegaly (group # 1) and in patients with different disease status (group #2).

Eligibility Criteria

Inclusion Criteria: * De novo patients with acromegaly (group # 1), diagnosed according to Endocrine Society guidelines, * Age equal to18 years or older * Acromegalic patients with different disease status (group #2) * Age equal to18 years or older Exclusion Criteria: * Cardiorespiratory, neurological or musculoskeletal disorder * Previous orthopaedic surgery * Previous lower limbs traumatic injuries

Contact & Investigator

Central Contact

Sara Farina, Doctor

✉ sara.farina@unimi.it

📞 +393386822298

Principal Investigator

Giovanni Vitale

PRINCIPAL INVESTIGATOR

Istituto Auxologico Italiano IRCCS

Frequently Asked Questions

Who can join the NCT05964712 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Acromegaly. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05964712 currently recruiting?

Yes, NCT05964712 is actively recruiting participants. Contact the research team at sara.farina@unimi.it for enrollment information.

Where is the NCT05964712 trial being conducted?

This trial is being conducted at Milan, Italy.

Who is sponsoring the NCT05964712 clinical trial?

NCT05964712 is sponsored by Istituto Auxologico Italiano. The principal investigator is Giovanni Vitale at Istituto Auxologico Italiano IRCCS. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology